| 行业基本情况 | | | | --- | --- | --- | | 收盘点位 | | 8323.7 | | 52 | 周最高 | 9323.49 | | 52 | 周最低 | 6876.88 | 行业相对指数表现 证券研究报告：医药生物|行业周报 发布时间：2026-03-02 行业投资评级 强于大市|维持 -8% -4% 0% 4% 8% 12% 16% 20% 24% 2025-03 2025-05 2025-07 2025-10 2025-12 2026-02 医药生物 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 分析师:陈灿 SAC 登记编号:S1340525070001 Email:chencan@cnpsec.com 近期研究报告 《黎明已至，国产争先》 - 2026.02.27 医药生物行业报告 （2026.02.23-2026.02.27） 手术机器人行业或出台收费标准，龙头公司有望迎 加速发展 ⚫ 本周主题 手术机器人行业或出台收费标准，龙头公司有望迎加速发展 ...

| 华安研究 2026年3月金股组合 | 归母净利润（百万元） | 归母净利润增速 | 营业收入（百万元） | 营业收入增速 | eps | pe(其余有说明) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 行业 | 金股代码 | 金股 | 核心推荐逻辑 | 风险提示 | 研究员 | 报告依据 | 2024A | 2025E | 2026E | 2024A | 2025E | 2026E | 2024A | 2025E | 2026E | 2024A | 2025E | 2026E | 2024A | 2025E | 2 ...

Group 1 - The core viewpoint is that Citic Securities is optimistic about the surgical robot sector, noting significant recent gains in related Hong Kong stocks due to positive catalysts from recent bidding announcements [1] - The company suggests continued attention to investment opportunities in the surgical robot sector, indicating a favorable outlook for its future [1] - In the A-share market, certain stocks in the brain-computer interface sector experienced substantial increases before the Spring Festival, highlighting potential investment themes in AI healthcare and brain-computer interfaces [1]

February 24, 2026 05:32 AM GMT 精锋医疗 | Asia Pacific 手术机器人先行者商业化进展 提速；首次覆盖，给予超配评 级 我们首次覆盖精锋医疗，给予超配（OW）评级，目标价75港 元。这是鉴于公司海外市场早期动能强劲、国内新增订单市 占率第一的表现，并在行业结构性增长潜力背景下，得到稳 健的临床反馈支撑。当前股价对应0.39倍市销增长比 （PSG），且前方催化剂充足，我们认为估值仍具上行空间。 具备结构性增长机遇的创新型内镜手术机器人企业：精锋医疗是微创手术机器人 领域的新兴领先者，有望充分受益于行业长期强劲增长。根据 Frost & Sullivan （F&S）预测，全球手术机器人市场规模将由 2024年的212亿美元 增长至 2033年 的842亿美元，对应 16.6%的复合年增长率（CAGR）；同期中国市场预计将由 72 亿元人民币大幅增长至 1,020亿元人民币，对应 34.3%的CAGR，增速快于全球。 鉴于政策支持、进口替代加速推进、行业渗透率持续提升，以及我们近期 AlphaWise中国医院调研反馈积极，我们认为精锋医疗将成为该结构性趋势下的核 心受益者之 ...

Core Insights - Medtronic has made significant advancements in the surgical robotics field with the FDA approval of its spinal robot platform Stealth AXiS and the successful commercial surgeries using the Hugo RAS system, indicating a shift in competition from single-device functionality to integrated system capabilities and data management [1][4][7]. Group 1: Spinal Robotics - The Stealth AXiS system represents a qualitative leap in Medtronic's spinal robotics, integrating preoperative planning, intraoperative navigation, and robotic execution into a seamless platform [4]. - The innovative LiveAlign technology allows for real-time tracking of anatomical changes during surgery, addressing the core challenge of dynamic anatomical displacement, thus enhancing surgical precision and reducing radiation exposure [6]. Group 2: Soft Tissue Robotics - The Hugo system's successful implementation in a prostatectomy at the Cleveland Clinic demonstrates its viability in top-tier medical institutions and reflects Medtronic's commitment to personalized medicine [7][9]. - Hugo's modular design offers flexibility in configuration, making it more appealing for outpatient surgical centers, while Medtronic's comprehensive product offerings across various surgical modalities enhance customer loyalty [9]. Group 3: AiBLE Ecosystem - Medtronic's AiBLE intelligent ecosystem connects the spinal and soft tissue robotics, positioning both systems as integral data nodes within a larger digital infrastructure that supports continuous improvement through data feedback [10]. - The competitive landscape is shifting, with Medtronic's emphasis on addressing uncertainties in surgery through advanced technologies like LiveAlign, contrasting with the closed systems of competitors like Intuitive Surgical [10].

经济观察网近期多家机构发布报告关注微创机器人-B，看好其作为国产手术机器人领军企业的发展前 景。华安证券（600909）指出，公司核心产品图迈腔镜手术机器人系列竞争优势显著，截至2025年底全 球累计商业化订单超过160台，其中2025年新获订单近120台，并预计2025-2027年营业收入将快速提 升。摩根大通重申公司为医疗科技行业首选股，维持"增持"评级，透露图迈全球累计订单截至2026年1 月20日已突破180台，并上调了2026-2027年的装机量及营收预测。华安证券同期报告预计公司2026年有 望实现盈亏平衡，长期盈利能力将得到改善。 微创机器人-B股价近期呈现震荡走势。截至2026年2月12日，股价报26.08港元，当日下跌0.61%，近5日 累计上涨2.84%，但20日跌幅为4.82%。成交方面，2月10日成交额达2.11亿港元，单日涨幅3.72%，显示 短期活跃度有所提升；技术指标上，股价目前低于20日均线，MACD柱状图为负值，短期动能偏弱。 以上内容基于公开资料整理，不构成投资建议。 股票近期走势 ...

Summary of the Conference Call for Jingfeng Medical Industry Overview - The rise of high-end medical manufacturing in China is driving the development of domestic surgical robots, with companies like Jingfeng Medical showcasing differentiated advantages in remote and single-port surgical robots, particularly in developing countries where there is significant unmet clinical demand [2][3] Company Performance - Jingfeng Medical is recognized as a benchmark enterprise in the domestic laparoscopic surgical robot market, holding approximately 20% market share, second only to the Da Vinci system [4] - The company is expected to achieve significant overseas success, with installation and shipment volumes nearing 50 units by 2025, and rapid growth anticipated in 2026 [5] Financial Projections - Revenue forecasts for Jingfeng Medical are projected at 432 million yuan, 811 million yuan, and 1.232 billion yuan for the years 2025, 2026, and 2027 respectively [6] - A target price of 773.2 yuan or 79.57 HKD is set based on a 35x price-to-sales ratio for 2026, with an initial rating of "buy" [6] Core Technologies and Products - Jingfeng Medical is the first in China and the second globally to receive certifications for multi-port, single-port, and natural orifice surgical robots [7] - The flagship product, MSP2000, is the world's first integrated single-multi-port robotic surgical system, which received the C1 certification in October 2025 [7] Commercialization Progress - Since the commercialization of the multi-port laparoscopic surgical robot at the end of 2022, Jingfeng Medical has ranked first in domestic sales, covering over 220 hospitals across more than 30 provinces [8] - The company has signed sales agreements for 118 core products by the end of 2025, with 72 units destined for international markets, indicating a scaling global presence [8] Innovative Solutions - The company has launched a tri-modal surgical solution that integrates multi-port, single-port, and remote capabilities, reducing hospital acquisition costs and enhancing operational efficiency [9] - Its adaptability covers various laparoscopic surgical scenarios, including urology and gynecology, facilitated by high-precision control systems and low-latency remote systems [9] Management and R&D Strength - Founded by experienced professionals, Jingfeng Medical has a cross-disciplinary R&D team of 265 members, holding 453 authorized patents and 213 pending applications, ranking first among domestic peers [10] - The management team has extensive backgrounds in leading medical and precision instrument companies, providing a solid foundation for rapid growth [10] Future Development Prospects - With increasing installation volumes and enhanced product performance, the company is expected to achieve profitability by 2026, maintaining stable gross margins while expanding market penetration [11] - Continuous investment in R&D and marketing is anticipated to solidify its industry-leading position and drive further breakthroughs [11] Advantages of Robotic Surgery - Robotic surgical systems offer significant advantages over traditional laparoscopic surgery, including reduced impact from human factors like fatigue and emotion, and a wide range of applications across various medical fields [12] Market Comparison - The global laparoscopic surgical robot market is rapidly expanding, with projections indicating substantial growth in both installation volumes and market size through 2033 [16] - In China, the market is expected to grow significantly, with installation numbers projected to rise from 134 units in 2019 to 511 units by 2024, reflecting a compound annual growth rate of approximately 30% [20] Competitive Landscape - In China, 13 multi-port laparoscopic surgical robots have received regulatory approval, with 11 being domestic brands, showcasing a competitive local market [21] - Jingfeng Medical's products are noted for their affordability and advanced technology, allowing for widespread application in various hospital settings [21] International Expansion - Jingfeng Medical has established a robust commercialization team and has made significant strides in international markets, including obtaining CE certification in Europe and expanding into Southeast Asia [22][23] Conclusion - Jingfeng Medical is positioned for substantial growth in the surgical robot market, with innovative products, strong financial projections, and a commitment to expanding both domestic and international presence [24]

国泰海通证券发布研报称，自精锋多孔腔镜手术机器人于2022年12月商业化以来，于2024年在中国售出 了20台精锋多孔腔镜手术机器人，在国内手术机器人制造商中排名第一。此外，2025年以来，精锋医疗 国际化引擎全速启动，海外订单量迎来爆发式增长，截至2025年底，公司已签订的118台核心产品的全 球销售协议中，海外国家占72台。 精锋医疗-B(02675)午后涨超12%，截至发稿，涨11.33%，报64.85港元，成交额3517.46万港元。 消息面上，国家医保局近日出台手术机器人收费指南。国信证券表示，受益于手术机器人行业技术革 新、临床需求及政策红利，全球及中国市场规模持续高速增长，其中中国单孔及自然腔道机器人细分赛 道增速尤为突出。建议积极关注国产手术机器人厂家的进口替代及出海进程。 ...

Group 1: Precision Medicine and Robotics - The report highlights Jingfeng Medical-B as a leader in surgical robotics in China, driving advancements in surgical procedures through continuous technological innovation, with rapid growth in global clinical surgeries and domestic sales [2][3] - The company is projected to achieve revenues of 432 million, 811 million, and 1.236 billion yuan from 2025 to 2027, with a target price of 73.20 yuan for 2026 based on a 35X PS valuation [3] - Jingfeng Medical has established a comprehensive surgical solution with its innovative multi-port and single-port robotic systems, becoming the first in China and the second globally to obtain regulatory approval for multiple robotic systems [3][4] Group 2: Market Performance and Sales Growth - In 2024, Jingfeng Medical sold 20 multi-port surgical robots, ranking first among domestic manufacturers, with clinical applications covering over 220 hospitals across 30 provinces in China [4] - The company's total revenue is expected to increase from 48 million yuan in 2023 to 160 million yuan in 2024, with a significant rise from 30 million yuan in the first half of 2024 to 149 million yuan in the first half of 2025 [4] - The report indicates that Jingfeng Medical's international expansion has led to explosive growth in overseas orders, with 72 out of 118 signed global sales agreements for core products being from overseas markets [5] Group 3: Precision Manufacturing and Emerging Industries - The report covers Xingrui Technology as a leading precision manufacturing enterprise in China, focusing on automotive electronics and actively expanding into emerging industries, with a target price of 32.11 yuan [6][8] - Revenue projections for Xingrui Technology are 1.626 billion, 1.980 billion, and 2.482 billion yuan from 2025 to 2027, with an expected EPS of 0.48, 0.69, and 0.95 yuan respectively [6] - The company has established a robust product matrix, including electronic connectors and structural components, with applications in new energy vehicle systems and consumer electronics, enhancing its competitive advantage in the automotive electronics sector [7] Group 4: Strategic Partnerships and Market Expansion - Xingrui Technology has formed strategic partnerships to expand into the liquid cooling industry, collaborating with Green Cloud to develop advanced technologies and products for data centers [8] - The company has a strong customer base, collaborating with renowned brands in consumer electronics and new energy sectors, and has established a global business layout with factories in multiple locations [7][8] - The report emphasizes the potential for Xingrui Technology to benefit from the growing demand for liquid cooling solutions driven by energy efficiency upgrades in data centers [8]

Summary of Key Points from Conference Call Records Industry Overview 1. PCB (Printed Circuit Board) - The PCB sector has shown weak performance since Q4 of last year, primarily due to divergent market views on orthogonal backplane solutions, with some believing they may be replaced by copper cables/CPO or delayed until 2028. However, the orthogonal backplane is currently progressing steadily and is expected to enter mass production in H2 2027. Leading companies are experiencing stock price stagnation due to these divergences, highlighting their cost-effectiveness. Recommended companies include Dongshan Precision, Shenghong Technology, and Huidian Co. [1] - The CoWoP (Chip on Wafer on PCB) solution has stronger certainty, can reduce costs, improve efficiency, and bypass the shortage of substrate capacity. The value per square meter of PCB may increase several times, potentially reaching tenfold, with product launches expected by the end of 2027 and full implementation in 2028. Recommended companies in this direction include Pengding Holdings, Shennan Circuit, and Xinsong Technology. [1] 2. Storage - Contract prices remain in an upward cycle despite fluctuations in spot prices. Module companies are expected to see explosive Q1 performance, with Jiangbolong and Demingli realizing low-priced inventory. Recommended design companies include Zhaoyi Innovation (with a profit expectation of 6 billion) and Puran Co., Beijing Junzheng, and Hengshuo Co. [2] - Demand for memory modules is driven by AI servers and general servers, with recommendations for Lanke Technology (long-term profit of 10 billion) and Jucheng Co. (long-term profit of 1.5 billion). [2] 3. Communication - The recent decline in optical modules is related to the pullback of US tech stocks and speculation around CPO concepts. However, industry sources (such as Coherent and Xuchuang) indicate that CPO's potential to replace optical modules in ScaleOut scenarios is low, suggesting that short-term speculation may be excessive. [2] - North American cloud service providers have exceeded capital expenditure guidance for 2026 (620 billion, up 65% year-on-year), indicating potential accelerated demand for optical modules in 2027. Key upcoming catalysts include Nvidia's quarterly report (February 26), GTC conference (March), and OFC exhibition (NPO product showcase). Recommended companies include Zhongji Xuchuang, Xinyisheng, and Dongshan Precision. [2] - For copper connections as a Plan B alternative to orthogonal backplanes, companies to watch include Luxshare Precision, Wokai Nuclear Materials, and Huiju Technology (with potential for stock doubling). [2] - The price of scattered fiber has surged in the short term (from 25 to 50 yuan), but the low willingness of operators to raise prices raises doubts about long-term sustainability. [2] 4. Computing - Domestic computing resources are in short supply, with the recent downtime of Qianwen highlighting the scarcity of AI foundational resources. The demand for CPUs is expected to rise due to increased usage of agents compared to chatbots. Recommended companies include Haiguang Information (benefiting from both CPU and GPU), Cambrian (leading domestic AI chip manufacturer), and Tianshu Zhixin (expected to accelerate integration with leading players). [2] - Cloud infrastructure resources are expected to benefit from price increases, with recommendations for Kingsoft Cloud, Wangsu Technology, and Fourth Paradigm. [2] - In the AI application sector, the recent drop in overseas software and restructuring of SaaS business models may lead to a narrative reversal with the launch of native agent products in Q3 2026. Companies to watch include Alibaba for 2C entry reconstruction and third-party AI agents like TaxFriend, Zhongkong Technology, and Dingjie Smart. [2] 5. Media - Tencent has faced a decline due to market concerns over potential tax increases on internet platforms, although there is no space for increased game value-added tax. The company remains recommended despite rumors of Q4 earnings downgrades, maintaining a PE ratio of 15 times, which still offers value. [3] - The download situation for the Yuanbao app remains stable, and Tencent's AI capabilities may be closing the gap with larger competitors. [3] - In gaming, companies with upcoming catalysts such as Giant Network and Perfect World are recommended for short-term focus, while Century Huatong and Kaiying Network are suggested for medium to long-term attention due to expected catalysts. [3] - Tencent's establishment of a separate AI comic app is beneficial for the production side, which is entering a period of profitability. Recommendations include Kuaishou, Huanrui, and Rongxin. [3] 6. Pharmaceuticals - Attention is drawn to the update of the essential drug catalog, which may accelerate progress. [4] - The probability of inclusion in the essential drug catalog is high for unique products, with several specific products from companies like Jichuan Pharmaceutical and Panlong Pharmaceutical being highlighted. [4] - Emphasis on the global competitiveness of the innovative drug industry chain, with a focus on new-generation ADCs, IOs, small nucleic acids, and CGT. Recommended companies include Kanghong, Yingen, Yunding, and Chengdu Xian Dao. [4] - The brain-computer interface theme is noted, with a potential showcase of non-invasive products during the Spring Festival and a semi-invasive product approval for Borui Kang in March. [4] - Recommendations include Meihua Medical, Dongwei Semiconductor, and Sanbo Brain Science. [5] - The surgical robot sector is expected to see comprehensive implementation of charging policies before August, with overseas orders doubling and maintaining high growth in 2027. Key types include laparoscopic and orthopedic robots, with strong overseas performance for laparoscopic robots. Recommended companies include MicroPort, Jingfeng Medical, Tianzhihang, and Sanyou Medical. [6]